CorMedix 在提交给美国证券交易委员会（SEC）的文件中披露，法院已于7月24日对该公司衍生诉讼的和解方案给予了初步批准。这一关键进展，标志着公司法律纠纷的解决向前迈出了重要一步。根据文件内容，该和解协议已经获得法庭的初步认可，后续各项程序有望逐步推进。CorMedix 正通过这一司法程序，力求化解股东衍生诉讼带来的潜在法律风险。
CorMedix 在提交给美国证券交易委员会（SEC）的文件中披露，法院已于7月24日对该公司衍生诉讼的和解方案给予了初步批准。这一关键进展，标志着公司法律纠纷的解决向前迈出了重要一步。根据文件内容，该和解协议已经获得法庭的初步认可，后续各项程序有望逐步推进。CorMedix 正通过这一司法程序，力求化解股东衍生诉讼带来的潜在法律风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.